Fatema Tuz Zohora

Fatema Tuz Zohora

Auto-generated profile, based on publicly available information

Fatema Tuz Zohora

Jeffrey Cheah School of Medicine and Health Sciences, Monash University, Subang Jaya, Malaysia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2024 in Immunopharmacology and Immunotoxicology
Verified
Journal Article
Closed access
MAMansur Aliyu
Mansur Aliyu
FZFatema Tuz Zohora
Fatema Tuz Zohora
ACAyca Ceylan
Ayca Ceylan
FHFariha Hossain
Fariha Hossain
RYReza Yazdani
Reza Yazdani
GAGholamreza Azizi
Gholamreza Azizi
Background: Multiple sclerosis (MS) is a central nervous system (CNS) demyelinating autoimmune disease with increasing global prevalence. It predominantly affects females, especially those of European descent. The interplay between environmental factors and genetic predisposition plays a crucial role in MS etiopathogenesis. Methods: We search recent relevant literature on reputable databases, which include, PubMed, Embase, Web of Science, Scopus, ScienceGirect using the following keywords: multiple sclerosis, pathogenesis, autoimmunity, demyelination, therapy, immunotherapy. Results: Various animal models have been utilized to study MS etiopathogenesis and therapeutics. Autoreative T cells within the CNS recruit myeloid cells through chemokine expression, leading to the secretion of inflammatory cytokines driving the MS pathogenesis, resulting in demyelination, gliosis, and axonal loss. Key players include T cell lymphocytes (CD4+ and CD8+), microbiota B cells, and neutrophils. Signaling dysregulation in inflammation pathways and the immunogenetic basis of MS are essential considerations. The pathogenesis of MS involves demyelination, gliosis, and axonal loss driven by inflammatory cytokines. While T cells are traditionally recognized as central to MS, evidence suggests a significant role for B cells and neutrophils. High neutrophil-to-lymphocyte ratios correlate with MS severity, indicating their contribution to disease progression. Dysregulated signaling pathways further exacerbate MS progression. Conclusion: MS remains incurable, but disease-modifying therapies, monoclonal antibodies, and immunomodulatory drugs offer hope for patients. Ongoing research into the immunogenetics and immunoregulatory roles of gut microbiota continues to shed light on potential therapeutic avenues. Understanding the complex interplay between genetic predisposition, environmental factors, and immune dysregulation is critical for developing effective treatments for MS.

8 July 2023 in Heliyon
Verified
Journal Article
Open access
FZFatema Tuz Zohora
Fatema Tuz Zohora
MAMansur Aliyu
Mansur Aliyu
ASAli Akbar Saboor-Yaraghi
Ali Akbar Saboor-Yaraghi
The bone marrow (BM) plays a pivotal role in homeostasis by supporting hematopoiesis and immune cells' activation, maturation, interaction, and deployment. “BMSC-derived secretome” refers to the complete repertoire of secreted molecules, including nucleic acids, chemokines, growth factors, cytokines, and lipids from BM-derived mesenchymal stem cells (BMSCs). BMSC-derived secretomes are the current molecular platform for acellular therapy. Secretomes are highly manipulable and can be synthesised in vast quantities using commercially accessible cell lines in the laboratory. Secretomes are less likely to elicit an immunological response because they contain fewer surface proteins. Moreover, the delivery of BMSC-derived secretomes has been shown in numerous studies to be an effective, cell-free therapy method for alleviating the symptoms of inflammatory and degenerative diseases. As a result, secretome delivery from BMSCs has the same therapeutic effects as BMSCs transplantation but may have fewer adverse effects. Additionally, BMSCs’ secretome has therapeutic promise for organoids and parabiosis studies. This review focuses on recent advances in secretome-based cell-free therapy, including its manipulation, isolation, characterisation, and delivery systems. The diverse bioactive molecules of secretomes that successfully treat inflammatory and degenerative diseases of the musculoskeletal, cardiovascular, nervous, respiratory, reproductive, gastrointestinal, and anti-ageing systems were also examined in this review. However, secretome-based therapy has some unfavourable side effects that may restrict its uses. Some of the adverse effects of this modal therapy were briefly mentioned in this review.

15 April 2026 in OBM Genetics
Verified
Journal Article
Open access
TUTaslim Uddin
Taslim Uddin
FZFatema Tuz Zohora
Fatema Tuz Zohora
TKTajmin Khanam
Tajmin Khanam
MAMoumita Akter
Moumita Akter
LHLubaba Ibnul Himika
Lubaba Ibnul Himika
SPShahrin Akter Pinky
Shahrin Akter Pinky
Changes in the environment driven by climate change are becoming significant stressors that impact brain function, but the connections between these changes and neural plasticity remain unclear. This review aims to offer a comprehensive synthesis of the impact of climate-related stressors on neural plasticity via genetic and epigenetic mechanisms. A structured literature search (2000-2025) was conducted using PubMed, Scopus, and Web of Science, integrating evidence from in vitro, animal, and human studies. Findings indicate that stressors such as heat, pollution, psychosocial adversity, and hypoxia alter neural plasticity through interconnected pathways, such as oxidative stress responses, mitochondrial adaptation, neurotrophic signaling, and epigenetic regulation. The strength of evidence varies; mechanistic insights are primarily obtained from experimental models, whereas human data are mostly associative. We propose a framework for an adaptive-maladaptive continuum based on the intensity, duration, and timing of stressors in development. Overall, this review highlights key knowledge gaps and provides a structured roadmap to improve causal inference and translational relevance.

31 March 2025 in Biomedical and Pharmacology Journal
Verified
Journal Article
Open access
SMSumiya Sharmin Mou
Sumiya Sharmin Mou
FZFatema- Tuz- Zohora
Fatema- Tuz- Zohora
SASeagufta Afrin
Seagufta Afrin
STSolaiman Hossain Tuhin
Solaiman Hossain Tuhin
DMDr. Abdul Abdul Muhit
Dr. Abdul Abdul Muhit
FAFiroj Ahmed
Firoj Ahmed
This study evaluates the chemical and biological properties of Pterocarpus santalinus leaf methanolic extract to establish its scientific basis for potential therapeutic applications. The phytochemical analysis revealed the presence of 595.04 mg/g flavonoids (quercetin equivalent) and 69 mg/g phenolic compounds (gallic acid equivalent), underscoring its antioxidant potential. The extract exhibited DPPH radical scavenging activity with an IC50 of 337.79 µg/ml, indicating moderate antioxidant capacity. Additionally, mild antimicrobial activity was observed against Escherichia coli and Aspergillus niger. The cytotoxic effects of the extract were assessed in HeLa cells, demonstrating a concentration-dependent relationship. At concentrations of 100 µg/ml and 200 µg/ml, cell viability remained above 95%, indicating non-toxic effects. However, at 500 µg/ml, a significant decrease in cell viability to 20-30% was observed, with an LC50 value of 365.77 µg/ml, indicating substantial cytotoxicity at higher concentrations. These results suggest that while lower concentrations are safe, higher doses may induce cell death, necessitating the establishment of safe dosage ranges for therapeutic applications. The findings support the pharmacological potential of P. santalinus leaf extract, highlighting its relevance in antioxidant, antimicrobial, and anticancer research, and warrant further investigation to refine its medicinal applications.

17 June 2025 in Inflammopharmacology
Verified
Journal Article
Closed access
PDF file
MAMansur Aliyu
Mansur Aliyu
ASAli Akbar Saboor-Yaraghi
Ali Akbar Saboor-Yaraghi
MGMuhammad Ibrahim Getso
Muhammad Ibrahim Getso
FZFatema Tuz Zohora
Fatema Tuz Zohora

24 April 2026 in International Journal of Advances in Life Science and Technology
Verified
Journal Article
Closed access
SNSonia Nashid
Sonia Nashid
ASArifa Siddiqua
Arifa Siddiqua
GMGwaliwa Peter Mashaka
Gwaliwa Peter Mashaka
AOAbimbola Olaniran
Abimbola Olaniran
FZFatema Tuz Zohora
Fatema Tuz Zohora
The digital transformation of the American healthcare system is increasingly reliant on advanced artificial intelligence (AI) to address the twin challenges of predictive analysis and fraud detection. This review synthesizes literature from 2019 to 2025 to map the evolution of data-driven healthcare, from fundamental predictive analytics to advanced fraud detection. Early applications of Logistic Regression and Random Forests have evolved with the integration of deep learning tools, such as Convolutional Neural Networks (CNNs) and Reinforcement Learning (RL). This progression empowers more sophisticated, real-time decision-making, moving beyond simple forecasting to dynamic treatment protocols that imitate clinical precision and reduce mortality. Concurrently, the integration of AI with Internet of Medical Things (IoMT) devices provides remote patient monitoring, real-time diagnostics, and personalized care. For healthcare fraud detection, the field has progressed from rule-based systems to a new generation of AI models designed to tackle complex anomalies. Techniques like SMOTE and ROS have given way to more sophisticated approaches, including Graph-Based AI and advanced hybrid models (e.g., MHAMFD), which are better equipped to detect collusion, overutilization, and data tampering. However, the power of these models is constrained by standardization issues and data silos. The next frontier in this AI progression is defined by solutions that address these barriers. This review argues that federated learning, which allows models to be trained without centralizing sensitive patient data, and Explainable AI (XAI), which builds trust and transparency in black-box models, are essential for overcoming current limitations and ensuring an effective and equitable future for AI in healthcare.